Motif Bio (MTFB) has announced that four of its Iclaprim abstracts have been accepted for presentation at the upcoming European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2019).
The clinical-stage biopharmaceutical company has developed their iclaprim antibiotic for the treatment of “acute bacterial skin and skin structure infections.” The drug is designed to be effective against these life-threatening infections, often caused by multi-drug resistant Gram-positive bacteria, including MRSA (known as “superbugs”).
And commercial interest in the drug is building. Back in February, Motif Bio received a Complete Response Letter establishing a May 3 2019 meeting between the company and the FDA. In the letter, the FDA confirmed it had no questions over the clinical efficacy of iclaprim; rather, the administration sought to further evaluate any risk for liver toxicity.
If approved, the iclaprim fixed dose could help hospitals reduce the amount of resources required by hospitals to deliver an equivalent treatment.
Participation in the ECCMID will certainly add legitimacy and clout for iclaprim.
As one of the world’s premier events on clinical microbiology and infectious diseases, ECCMID served as both an educational and networking event for the over 12,000 experts in attendance.
The four sessions presented by Motif Bio will take place in Amsterdam from April 13-16. More information on the presentations, along with findings about iclaprim are available here.
For more news and updates on Motif Bio: